Scalper1 News
Bristol-Myers Squibb won approval in Japan for its all-oral hepatitis C virus (HCV) regimen, an expected but important development for the company as it carves out its place in the crowded HCV market. The stock was down a fraction in midday trading on the stock market today . Bristol-Myers Squibb’s (BMY) therapy is a combination of daclatasvir and asunaprevir , now known by the brand names Daklinza and Sunvepra, respectively. The approval was for Scalper1 News
Scalper1 News